At a glance
- Originator Tanabe Seiyaku
- Class Disease-modifying antirheumatics
- Mechanism of Action Interferon beta inhibitors; Interleukin 1 inhibitors; Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis